Low-Dose Triple Antihypertensive Combination Therapy in Patients with Hypertension: A Randomized, Double-Blind, Phase II Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hong, Soon Jun | - |
dc.contributor.author | Sung, Ki-Chul | - |
dc.contributor.author | Lim, Sang-Wook | - |
dc.contributor.author | Kim, Seok-Yeon | - |
dc.contributor.author | Kim, Weon | - |
dc.contributor.author | Shin, Jinho | - |
dc.contributor.author | Park, Sungha | - |
dc.contributor.author | Kim, Hae-Young | - |
dc.contributor.author | Rhee, Moo-Yong | - |
dc.date.accessioned | 2021-08-31T16:14:27Z | - |
dc.date.available | 2021-08-31T16:14:27Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2020 | - |
dc.identifier.issn | 1177-8881 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/59062 | - |
dc.description.abstract | Purpose: We evaluated the dose-responsiveness, efficacy, and safety of low-dose triple antihypertensive combination therapies in patients with mild-to-moderate hypertension. Patients and Methods: After a 1 to 2-week placebo run-in period, 248 patients were randomized to the half-dose triple combination (amlodipine 2.5 mg + losartan 25 mg + chlorthalidone 6.25 mg), third-dose triple combination (amlodipine 1.67 mg + losartan 16.67 mg + chlorthalidone 4.17 mg), quarter-dose triple combination (amlodipine 1.25 mg + losartan 12.5 mg + chlorthalidone 3.13mg), amlodipine 10mg, amlodipine 5mg, losartan 100mg, and placebo groups for 8 weeks. The primary outcome was the mean change in systolic blood pressure (SBP) from baseline to week 8. Results: The placebo-corrected SBP reductions of the half-dose, third-dose, quarter-dose combination, amlodipine 10 mg, amlodipine 5 mg and losartan 100 mg treatments were -17.2, -19.5, -14.9, -18.5, -11.3 and -9.9 mmHg, respectively. The BP control and response rates were significantly higher in the half-dose, third-dose, and quarter-dose combination groups than in the placebo group (all p < 0.01). Despite no intergroup differences in study drug-related adverse events, ankle circumference increased significantly in the amlodipine group compared to those in the combination treatment groups. The quarter-dose combination, amlodipine 5 mg, and losartan 100 mg groups showed similar SBP reduction and BP response rates. The SBP reduction and BP response rate in the third-dose and half-dose combination groups were not significantly different from those in the amlodipine 10 mg group but superior to those in the losartan 100 mg group. Conclusion: Low-dose triple combination therapies could be effective as antihypertensive therapies. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | DOVE MEDICAL PRESS LTD | - |
dc.subject | METAANALYSIS | - |
dc.subject | AMLODIPINE | - |
dc.subject | EFFICACY | - |
dc.subject | EVENTS | - |
dc.subject | SAFETY | - |
dc.subject | AGENTS | - |
dc.title | Low-Dose Triple Antihypertensive Combination Therapy in Patients with Hypertension: A Randomized, Double-Blind, Phase II Study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Hong, Soon Jun | - |
dc.contributor.affiliatedAuthor | Kim, Hae-Young | - |
dc.identifier.doi | 10.2147/DDDT.S286586 | - |
dc.identifier.scopusid | 2-s2.0-85099983293 | - |
dc.identifier.wosid | 000603676500001 | - |
dc.identifier.bibliographicCitation | DRUG DESIGN DEVELOPMENT AND THERAPY, v.14, pp.5735 - 5746 | - |
dc.relation.isPartOf | DRUG DESIGN DEVELOPMENT AND THERAPY | - |
dc.citation.title | DRUG DESIGN DEVELOPMENT AND THERAPY | - |
dc.citation.volume | 14 | - |
dc.citation.startPage | 5735 | - |
dc.citation.endPage | 5746 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.subject.keywordPlus | AMLODIPINE | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | EVENTS | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | AGENTS | - |
dc.subject.keywordAuthor | hypertension | - |
dc.subject.keywordAuthor | blood pressure | - |
dc.subject.keywordAuthor | combination therapy | - |
dc.subject.keywordAuthor | low-dose | - |
dc.subject.keywordAuthor | amlodipine | - |
dc.subject.keywordAuthor | losartan | - |
dc.subject.keywordAuthor | chlorthalidone | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.